BACKLeveraging Type 2 Cytokines to Enhance Cell-Based Therapy for Peripheral Arterial Diseases
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 25 August 2024]
We are inviting expressions of interest (EoI) for commercializing “Leveraging Type 2 Cytokines to Enhance Cell-Based Therapy for Peripheral Arterial Diseases” technology. The innovation is developed by Professor WONG Wing Tak Jack, Professor of School of Life Sciences of the Chinese University of Hong Kong (CUHK Reference: 24/SCI/1369).
The Technology
This invention aims to address the challenge of revascularization in Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential of type 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This invention also aims to enhance the muscle regeneration and revascularization for obese and diabetes individuals, holding promise for the further development and application of personalized healthcare. This innovative approach holds transformative potential, offering new possibilities for regenerative medicine, therapeutic strategies, and clinical applications in PAD and related vascular conditions. The objectives of this invention encompass several crucial aspects. Firstly, the optimal treatment conditions for IL-4 and IL-13 will be determined to evaluate their angiogenic effects on iPSC-ECs and iECs. Secondly, the impact of IL-4 and IL-13 on revascularization will be assessed using a hind limb ischemia model. Last but not least, the murine models of obesity (induced by high-fat diet) and diabetes (induced by injecting streptozotocin) will be established. The therapeutic potential of IL-4 and IL-13 in enhancing endothelial cell-based therapies for diabetes and obesity-related vascular complications will be determined. Overall, this invention provides a novel cell-based therapy for the treatment of PAD, holding promise for restoring the citizens’ mobility and decreasing the amputation rate of the society. The outcomes of this invention hold significant promise for advancing therapeutic strategies in regenerative medicine. By harnessing the angiogenic potential of IL-4 and IL-13 and optimizing the angiogenic capabilities of iPSC-ECs and iECs, the invention aims to make substantial improvements in the treatment of PAD and related vascular conditions, ultimately improving patient outcomes and quality of life
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Leveraging Type 2 Cytokines to Enhance Cell-Based Therapy for Peripheral Arterial Diseases
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 25 August 2024]
We are inviting expressions of interest (EoI) for commercializing “Leveraging Type 2 Cytokines to Enhance Cell-Based Therapy for Peripheral Arterial Diseases” technology. The innovation is developed by Professor WONG Wing Tak Jack, Professor of School of Life Sciences of the Chinese University of Hong Kong (CUHK Reference: 24/SCI/1369).
The Technology
This invention aims to address the challenge of revascularization in Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential of type 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This invention also aims to enhance the muscle regeneration and revascularization for obese and diabetes individuals, holding promise for the further development and application of personalized healthcare. This innovative approach holds transformative potential, offering new possibilities for regenerative medicine, therapeutic strategies, and clinical applications in PAD and related vascular conditions. The objectives of this invention encompass several crucial aspects. Firstly, the optimal treatment conditions for IL-4 and IL-13 will be determined to evaluate their angiogenic effects on iPSC-ECs and iECs. Secondly, the impact of IL-4 and IL-13 on revascularization will be assessed using a hind limb ischemia model. Last but not least, the murine models of obesity (induced by high-fat diet) and diabetes (induced by injecting streptozotocin) will be established. The therapeutic potential of IL-4 and IL-13 in enhancing endothelial cell-based therapies for diabetes and obesity-related vascular complications will be determined. Overall, this invention provides a novel cell-based therapy for the treatment of PAD, holding promise for restoring the citizens’ mobility and decreasing the amputation rate of the society. The outcomes of this invention hold significant promise for advancing therapeutic strategies in regenerative medicine. By harnessing the angiogenic potential of IL-4 and IL-13 and optimizing the angiogenic capabilities of iPSC-ECs and iECs, the invention aims to make substantial improvements in the treatment of PAD and related vascular conditions, ultimately improving patient outcomes and quality of life
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
N/A
Mr. Paul Cheung
Office of Research and Knowledge Transfer Services
Professor WONG Wing Tak Jack
N/A